Laboratory Corporation of America Holdings acquisition of Covance

19/2/2015

Public acquisition

Value:

$ 500 million

Status:

Completed

Date:

19/2/2015

Overview:

Laboratory Corporation has acquired Covance, a drug development company.
After the acquisition, Covance stopped trading on the New York Stock Exchange.
Each Covance share was valued at $75.76 in cash and 0.2686 LabCorp shares.

Rani Mehta - Journalist

Jurisdictions:

Canada
United States
Luxembourg

Deal type:

Public acquisition

Practice area:

M&A

Industry sector:

Pharmaceuticals and life sciences

Firms:

Hogan Lovells

Party: LabCorp (Acquirer)

Stikeman Elliott

Party: LabCorp (Acquirer)

Related deals